Similar to the antibody transfer model, anti-C5 therapy, as well as inhibition of the C5a–C5aR1-axis, would probably efficiently ameliorate complement-mediated injury in immunization-induced EBA and attenuate skin inflammation due to decreased leukocyte recruitment and activation by C5a. Here, C5AR1 is linked to acquired epidermolysis bullosa.